BioNTech (BNTX) Shares Drop After Phase 2/3 Trial Misses Primary Endpoint in Head and Neck Cancer Study

gurufocus.com · 2026-10-13

On October 13, 2026, BioNTech SE (NASDAQ: BNTX) shares declined roughly 6% following the announcement that its phase 2/3 AHEAD-MERIT trial evaluating the immuno

Read the full story at gurufocus.com →